Can a Two-Pronged immune attack shrink kidney tumors before surgery?
NCT ID NCT07741617
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial is testing whether giving a combination of an experimental immunotherapy (epalolitoworelimab) and a targeted therapy (lenvatinib) before and after surgery can improve outcomes for people with high-risk clear cell kidney cancer. The treatment is given first to shrink the tumor, then surgery removes it, and finally more immunotherapy is given to help prevent recurrence. The study will measure how well the tumor responds and how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- epalolitoworelimab (a PD-1/CTLA-4 combination antibody) combined with lenvatinib
- What this could lead to
- If successful, this approach could shrink high-risk kidney tumors before surgery and help prevent the cancer from coming back afterward, potentially improving long-term outcomes for patients.
- What could go wrong
- This is an early-phase, single-arm study with a small number of participants, so results may not be definitive. The combination of immunotherapy and lenvatinib can cause significant side effects, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors